U.S. Stock Market Movement | Weight-loss concept stocks rise, Eli Lilly up more than 6.8%
On Friday, US stocks related to the weight loss concept rose. As of the time of publication, Eli Lilly rose by over 6.8% to $903, while Novo Nordisk rose by nearly 4.6% to $134.04. In the second quarter, Eli Lilly's net profit was $2.97 billion, a year-on-year increase of 68%; revenue was $11.3 billion, a year-on-year growth of 36%, exceeding market expectations of $9.92 billion; adjusted earnings per share were $3.92, surpassing the expected $2.60. The weight loss drug Zepbound, which received FDA approval for listing in November last year, contributed revenue of $1.24 billion in the second full quarter, exceeding market expectations of $920 million. Due to the strong performance of the weight loss drug, the company has raised its fiscal year revenue guidance for the second time this year: both ends of the revenue guidance have increased by $3 billion to $45.4 to $46.6 billion; full-year adjusted earnings per share are $16.10-16.60, up from the previous guidance of $13.50 to $14
According to the Zhitong Finance and Economics APP, on Friday, US stocks related to weight loss concepts rose. As of the time of publication, Eli Lilly (LLY.US) rose by over 6.8% to $903, while Novo Nordisk (NVO.US) rose by nearly 4.6% to $134.04.
In the second quarter, Eli Lilly's net profit was $2.97 billion, a year-on-year increase of 68%; revenue was $11.3 billion, a year-on-year growth of 36%, exceeding market expectations of $9.92 billion; adjusted earnings per share were $3.92, surpassing the expected $2.60. The weight loss drug Zepbound, which received FDA approval in November last year, contributed $1.24 billion in revenue in the second full quarter, exceeding market expectations of $920 million. Due to the strong performance of the weight loss drug, the company has raised its full-year revenue guidance for the second time this year: both ends of the revenue guidance have been increased by $3 billion to $45.4 to $46.6 billion; adjusted earnings per share for the full year are $16.10 to $16.60, up from the previous guidance of $13.50 to $14